Daiichi Sankyo Articles
Daiichi Sankyo to support Phase I clinical study of anticoagulant activity reverser for edoxaban
25 April 2013
Japan briefs: Daiichi Sankyo launches silodosin in China; Fujifilm Diosynth UK unit commissioned
22 April 2013
MHLW joins Japan's first P-PP to facilitate R&D of new health technologies for the developing world
8 April 2013
Drug development deals for Kyowa Hakko/Adimab, Daiichi Sankyo/Amplimmune and Chugai/Debiopharm
8 January 2013
Brazil's atrial fibrillation market to grow at 31% annually over the next five years
19 December 2012
Ranbaxy Labs' Absorica debuts in USA
27 November 2012
ArQule and Daiichi Sankyo drop tivantinib trial in NSCLC
3 October 2012
Ranbaxy gains approval for new manufacturing plant in Malaysia
14 September 2012
US FDA pulls 27 Ranbaxy ANDAs approvals under consent decree
23 August 2012
Japan's drug majors post mixed financial results
31 July 2012
Ranbaxy sales rocket 55%, net rises four-fold
11 May 2012
Daiichi Sankyo and Ranbaxy launch Sevikar in Romania
19 April 2012
Daiichi Sankyo debuts bone cancer drug Ranmark in Japan
17 April 2012
Teva debuts generic of Provigil, Avapro and Avalide; Ranbaxy Crestor copy OKed in Canada
1 April 2012
Daiichi Sankyo files denosumab in Japan for osteoporosis
26 March 2012
Ranbaxy opens new plant in Morocco
12 March 2012
GSK and Daiichi Sankyo set up Japanese vaccines JV
2 March 2012
Daiichi Sankyo and Terumo link up for vaccine development
27 February 2012
Ranbaxy posts $586 million loss due to charges
23 February 2012
Additional indications in Japan for Diagnogreen and Sawacillin
22 February 2012
European approval for Roche skin cancer drug Zelboraf
21 February 2012
Japanese approval for Regnite and Ranmark
18 January 2012
Ranbaxy signs consent decree with US FDA over production practices
22 December 2011
EMA recommends approval of Roche’s Zelboraf
19 December 2011
Backing for Japanese approval of Regnite, Ranmark and Cancidas
5 December 2011
Daiichi Sankyo to license ARQ 092 from ArQule, under joint AKIP research collaboration
11 November 2011
AstraZeneca’s blood thinner Brilinta/Brilique demonstrates cost effectiveness; new Nexium indication filed in Japan
24 October 2011
Daiichi Sankyo admits supply problem with flu vaccine; gains approval for silodosin in China
23 September 2011
Ranbaxy posts 2nd-qtr 2011 net profit down 25%
7 August 2011
First-quarter FY 2012 net profit at Takeda jumps 18%, while that at Daiichi Sankyo slumps 23.5%
2 August 2011
Unprecedented survival results for B-MS Yervoy and Roche’s vemurafenib in melanoma discussed at ASCO
7 June 2011
Japan’s Daiichi Sankyo says nine-month 2010 sales boosted by Ranbaxy, but sees 4th-qtr loss due to interest costs at the Indian unit
1 February 2011
Daiichi Sankyo gets first European approval for combo antihypertensive drug Sevikar HCT
21 December 2010
Daiichi Sankyo US unit buys Roxro Pharma to gain pain drug SPRIX
14 December 2010
Ranbaxy 3rd-qtr 2010 net profit rockets 168% as sales rise 13%
12 November 2010
AstraZeneca earns $100 million selling Nexium co-promotion rights in Japan to Daiichi Sankyo
1 November 2010
Daiichi Sankyo launches flu drug Inavir inhaler in Japan; expands deal with ArQule; gets favorable patent ruling against Lupin
20 October 2010
Japanese regulator approves manufacture and marketing of Daiichi Sankyo/Biota’s flu drug Inavir
14 September 2010
Research briefs on Merck & Co’s boceprevir and Bayer’s Xarelto; legal updates from AstraZeneca and Daiichi Sankyo/Actavis
5 August 2010
US FDA approves Daiichi Sankyo’s combo hypertensive Tribenzor; J&J’s Tibotec files rilpivirine NDA
27 July 2010
Daiichi Sankyo to leverage Ranbaxy’s Romania and South Africa presence to market Tavanic
21 July 2010
Ranbaxy launches branded generic prasugrel in India
10 June 2010
Daiichi Sankyo to expand scope in Japan, setting up new generics unit with affiliate Ranbaxy
1 March 2010
Ranbaxy back in black in fourth quarter as US sales soar
26 February 2010
Daiichi Sankyo gains US FDA approval of Benicar to treat high BP in children and adolescent; names new VP medical affairs
12 February 2010
13.7% growth for Indian pharma recorded 13.7%to $9.43 billion in first three quarters of fiscal 2009-10
4 February 2010
Daiichi Sankyo initiates major Phase III trial for edoxaban in venous thromboembolism
4 February 2010
Daiichi Sankyo ups profit forecast by 13% on expected rupee gain related to Ranbaxy; files flu drug in Japan
1 February 2010
Batch of Japanese drug approvals, including for Taiho, Daiichi Sankyo and three for Novartis
20 January 2010
India’s Ranbaxy to enter vaccines market in deal with Biovel
19 January 2010
Impax Labs sued by Daiichi Sankyo and Genzyme after challenging Welchol patent in USA
18 January 2010
Ranbaxy to launch Daiichi Sankyo’s olmesartan in six African markets
23 December 2009
Japanese drug majors deliver mixed first-half results
2 November 2009
Big Pharma concludes M&A is not the new R&D
30 October 2009
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
